Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s EPO Franchise Takes A Hit From Regulatory Scrutiny

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the erythropoiesis-stimulating agent Procrit plunged 14 percent in the second quarter, causing J&J to revise sales expectations.

You may also be interested in...



Johnson & Johnson Tightens Organization To Find Savings

To save $1.3 billion to $1.6 billion a year, J&J is cutting 4,000 to 5,000 jobs in its pharma and Cordis segments and consolidating the Cordis franchise.

Johnson & Johnson Tightens Organization To Find Savings

To save $1.3 billion to $1.6 billion a year, J&J is cutting 4,000 to 5,000 jobs in its pharma and Cordis segments and consolidating the Cordis franchise.

J&J’s HIV Therapy Etravirine Shown To Have Antiviral Activity In Phase III Studies

Two Phase III trials found significantly more patients taking the non-nucleoside reverse transcriptase inhibitor reached undetectable viral load.

Related Content

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel